Diverse antigens, autoantibodies, Fc gamma receptors, neonatal Fc receptor, complement proteins, cytokines

This entry describes a broad array of immunological components rather than a single discrete molecular target. It includes antigens and autoantibodies that drive immune-mediated pathology, as well as Fc gamma receptors (FcγRs) and the neonatal Fc receptor (FcRn) which regulate antibody-mediated effector functions and immunoglobulin homeostasis (Roopenian & Akilesh, 2007, Nature Reviews Immunology). The list also encompasses complement proteins, which are essential for the innate immune response and inflammatory cascades (Ricklin et al., 2010, Nature Immunology), and cytokines, which serve as the primary signaling molecules for cellular communication during an immune response. These diverse factors are the collective targets of polyvalent therapies like Intravenous Immunoglobulin (IVIG), which exerts its therapeutic effect by interfering with multiple points in the inflammatory and autoimmune process (Galeotti et al., 2017, Nature Reviews Rheumatology). IVIG acts by neutralizing autoantibodies, saturating FcRn to accelerate the clearance of pathogenic IgG, and inhibiting the deposition of complement fragments on target tissues. It also modulates the expression and function of FcγRs on myeloid cells and alters the cytokine balance toward an anti-inflammatory state (Nimmerjahn & Ravetch, 2008, Nature Reviews Immunology). Because this list aggregates multiple distinct protein families and molecular entities, it is categorized as a set of targets for broad-spectrum immunomodulators rather than a specific, single drug-target interaction. This grouping is particularly relevant in the context of treating systemic autoimmune diseases, where multiple pathways of the immune system are simultaneously dysregulated.

Other names

Immune system mediatorsHumoral immune componentsIVIG targetsImmunological effectors

Broad-spectrum immunomodulation involving neutralization of autoantibodies, blockade of Fc receptors, saturation of the neonatal Fc receptor (FcRn) to increase pathogenic IgG clearance, inhibition of complement activation, and modulation of cytokine networks (Galeotti et al., 2017, Nature Reviews Rheumatology; Nimmerjahn & Ravetch, 2008, Nature Reviews Immunology).